Irinotecan hydrochloride liposomal (Luye Pharma Group)

盐酸伊立替康脂质体 (绿叶制药集团)

Report date: 2026/04/08 15:42:02

Base Information

Drug NameIrinotecan hydrochloride liposomal (Luye Pharma Group)
Drug Alias NameIrinotecan hydrochloride liposome Injection (Luye Pharma Group)Hydrochloride Irinotecan Floxurudine liposome Injection (Luye Pharma Group)LY 01610LY01610 (Luye Pharma Group)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaEsophageal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesLuye Pharma Group Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLuye Pharma Group LtdNanjing Luye Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursSmall Cell Lung CarcinomaEsophageal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A